HMG (Human Menopausal Gonadotropin)
Also known as: hMG, HP-hMG, highly purified hMG, human menopausal gonadotrophin, menotropins, Menopur
Gonadotropin / Fertility hormone preparation (NOTE: The abbreviation "HMG" in the provided literature also refers to multiple distinct biological entities: High
What it is
HMG (Human Menopausal Gonadotropin) is a fertility hormone preparation used in IVF and ovulation induction treatments to stimulate egg production. It works by delivering the hormones FSH and LH to drive follicle development in the ovaries. Approved for clinical fertility use in multiple countries; not available as a self-administered research compound.
The scientific side
Human menopausal gonadotropin (hMG) is a preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity (with highly purified formulations, HP-hMG, having human chorionic gonadotropin constituting most of its LH-like activity) used to stimulate ovarian follicle development. In controlled ovarian stimulation for IVF/ICSI, hMG promotes follicular growth and maturation. The abbreviation "HMG" in broader scientific literature also denotes: (1) High Mobility Group (HMG) proteins — a superfamily of abundant nuclear proteins that bind DNA and nucleosomes, induce structural changes in the chromatin fiber, and modulate transcription, replication, and other DNA-dependent processes; and (2) HMG-CoA reductase — the enzyme catalyzing the rate-limiting step in cholesterol/isoprenoid biosynthesis (conversion of HMG-CoA to mevalonate), which is the pharmacological target of statins.
Class: Gonadotropin / Fertility hormone preparation (NOTE: The abbreviation "HMG" in the provided literature also refers to multiple distinct biological entities: High Mobility Group proteins (chromatin-associated nuclear proteins), HMG-CoA reductase (an enzyme in cholesterol biosynthesis), and human menopausal gonadotropin (a fertility drug). This record focuses primarily on human menopausal gonadotropin (hMG) as a therapeutic agent, given the plurality of clinical/pharmacological abstracts. HMG-box protein and HMG-CoA reductase topics are noted separately.)
Administration & storage
- Administration
- Intramuscular injection — hMG in Japanese Black cattle superovulation study (PMID: 8720060)Subcutaneous injection — pulsatile GnRH component of modified hMG-GnRH protocol (20 µg/120 min SC) (PMID: 12081234)Injection (route not further specified) — hMG in FET endometrial preparation studies (PMID: 31814708PMID: 29676585)Injection (route not further specified) — hMG/HP-hMG in IVF/ICSI COS studies (PMID: 18583332PMID: 21776876PMID: 19298714)
- Storage
- No storage conditions for hMG preparations are described in the provided abstracts.
- Cautions
- Ovarian hyperstimulation syndrome (OHSS) has been reported with hMG-based protocols; the conventional hMG-hCG method was associated with a 25.7% OHSS rate in one study of hypogonadotropic amenorrhea patients, compared to 0% with a modified protocol.,Multiple pregnancy risk is associated with hMG stimulation; more than eight growing follicles were observed with the conventional hMG-hCG method in one study.,One abstract cited as a source for sequential CC/hMG vs hMG protocols is listed as a Retracted Publication — findings from this study should be interpreted with caution.,HP-hMG and traditional hMG preparations differ in purity and LH-activity source (hCG constitutes most LH-like activity in HP-hMG); clinical outcomes may differ between formulations (PMID: 19298714, PMID: 20500109).,Sterile technique is essential for any injectable preparation.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Controlled ovarian stimulation (COS) for IVF/ICSI Human RCT
- RCT of 280 patients: HP-hMG vs rFSH in GnRH antagonist cycles showed no significant difference in ongoing pregnancy rate per started cycle (35.0% vs 32.1%, P=0.61). rFSH produced more oocytes (14.4 vs 11.3, P=0.001); estradiol was higher in HP-hMG group at end of stimulation. PMID 18583332 Bosch et al., Human Reproduction, 2008
- Retrospective case-control (760 patients): rFSH yielded significantly more oocytes and mature oocytes than HP-hMG. No significant difference in clinical pregnancy rate (49.5% vs 48.9%, P=0.92) or delivery rate (42.9% vs 43.4%, P=0.96). Average starting dose: rFSH 152.7±41.1 IU vs HP-hMG 228.8±68.7 IU. PMID 21776876 Petanovski et al., Medicinski Arhiv, 2011
- Economic model based on RCT meta-analysis: average cost per live birth HP-hMG €9,996 vs rFSH €13,009 (P<0.0001); average treatment cost HP-hMG €3,635 vs rFSH €4,103; HP-hMG was dominant treatment strategy. PMID 19192340 Connolly et al., Reproductive Biomedicine Online, 2008
- Discrete event simulation in predicted high-responders (MEGASET-HR trial data): comparable live birth rates (161 vs 152 per 310 patients). Total cost saving per live birth with HP-hMG vs rFSH was US$3,024, driven by fewer embryo transfers and reduced OHSS rate. PMID 37480456 Khair et al., PharmacoEconomics Open, 2023
- Endometrial preparation for frozen-thawed embryo transfer (FET) Human observational
- Retrospective cohort (5,901 FET cycles): hMG stimulation alone produced lower clinical pregnancy rates (47.02%) compared to letrozole (52.07%) or letrozole+hMG (52.26%), and higher miscarriage rates (14.78% vs 10.53% letrozole). Neonatal outcomes similar across groups. PMID 31814708 Lin et al., Drug Design, Development and Therapy, 2019
- Retrospective analysis (5,070 FET cycles): modified hMG stimulated group had significantly higher clinical pregnancy and live birth rates than natural cycle, HRT, or letrozole groups (p<0.05). PMID 29676585 Huang et al., Gynecological Endocrinology, 2018
- Ovulation induction in clomiphene-resistant women Human RCT
- RCT (90 women): sequential CC/hMG regimen produced significantly higher pregnancy rate (26.7%) vs hMG alone (6.7%, p<0.05) and used significantly lower total gonadotropin dose (295.2±75.5 IU vs 625.3±65.0 IU). NOTE: This article was listed as a Retracted Publication. PMID 23080548 Abdelazim & Makhlouf, Archives of Gynecology and Obstetrics, 2013
- Ovulation induction in severe hypogonadotropic amenorrhea Human observational
- Controlled clinical trial (34 cycles, 20 women): modified hMG-GnRH method achieved 100% ovulation rate, <3 growing follicles in 81.8% of patients, 0% OHSS, no multiple pregnancies, and pregnancy in 3/5 patients who had failed sequential hMG-GnRH, compared to 25.7% OHSS rate with conventional hMG-hCG method. PMID 12081234 Yokoi et al., Endocrine Journal, 2002
- IVF outcome improvement in patients with high basal FSH/LH ratio Human observational
- Preliminary retrospective study: HMG produced significantly higher number of top-quality embryos (3.9±3.1 vs 2.5±1.7, P<0.05), higher implantation (27.9% vs 5.3%, P=0.003) and clinical pregnancy rates (44.4% vs 11.1%, P<0.02) vs rFSH in patients with high basal FSH/LH ratio. PMID 19192340 Orvieto et al., Reproductive Biomedicine Online, 2009
- Superovulation in cattle (veterinary use) Animal studies only
- 64 Japanese Black parous cows: 900 IU hMG produced significantly more recovered ova/embryos than FSH (P<0.05). Highest percentage of high-quality transferable embryos at 600 IU hMG. Study suggests 600 IU for 3 days is sufficient; 2-day treatment also possible. PMID 8720060 Sugano et al., Journal of Veterinary Medical Science, 1995
- HMG proteins (High Mobility Group) — roles in chromatin, transcription, and disease Mixed
- Review: HMG proteins are a superfamily of abundant nuclear proteins binding DNA and nucleosomes, inducing chromatin structural changes. Their expression is developmentally regulated; altered HMG levels lead to developmental abnormalities and disease. PMID 17169561 Hock et al., Trends in Cell Biology, 2007
- Review: HMG proteins are architectural elements of chromatin that dynamically modulate DNA-dependent processes by constantly moving around the chromatin fiber. PMID 20123065 Catez & Hock, Biochimica et Biophysica Acta, 2010
- Review: HMG-box domain (~75 amino acids) mediates DNA binding — either non-sequence-specific (HMGB-type) or sequence-specific (transcription factor type); both types bind non-B-form DNA structures with high affinity. PMID 17599239 Stros et al., Cellular and Molecular Life Sciences, 2007
Safety signals
- Ovarian hyperstimulation syndrome (OHSS): 25.7% incidence with conventional hMG-hCG method in hypogonadotropic amenorrhea patients; 20.0% with step-down method; 0% with modified hMG-GnRH method PMID 12081234
- Multiple pregnancy risk associated with conventional hMG stimulation: more than 8 growing follicles observed in patients treated with conventional hMG-hCG method PMID 12081234
- Higher ectopic pregnancy rate with hMG-alone endometrial preparation (1.83%) compared to letrozole (0.97%) in FET cycles PMID 31814708
- Higher miscarriage rate with hMG-alone stimulation (14.78%) compared to letrozole (10.53%) in FET cycles PMID 31814708
Contraindications
- No explicit contraindications for hMG (human menopausal gonadotropin) are stated in the provided abstracts.
Protocol
75 iu subcutaneous injection, 3x per week. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Injection (route not further specified in abstract) | 150 IU hMG every two days (stimulation group) or added if follicular diameter <14 mm on day 10 in letrozole+hMG group | From cycle day 10-12 (hMG group); variable (letrozole+hMG group) | human | Research PMID 31814708 |
| Not specified in abstract | Sequential CC/hMG: clomiphene citrate 100 mg/day for 5 days, then hMG 75 IU for 4 days; hMG-only group: low-dose step-up protocol for 10-14 days (total dose 625.3±65.0 IU) | 10-14 days (hMG group); 4 days hMG component (CC/hMG group) | human | Research PMID 23080548 |
| Subcutaneous (pulsatile GnRH, 20 µg/120 min SC); hMG route not further specified | Modified hMG-GnRH: daily hMG (dose not specified per day) combined with pulsatile GnRH 10 µg, then GnRH changed to 20 µg when follicle diameter reached 11-13 mm; conventional method: 150 IU/day hMG; step-down method: 150 IU decreasing to 75 IU when follicle diameter 11-13 mm | Until follicle diameter reached 11-13 mm | human | Research PMID 12081234 |
| Not specified in abstract | HP-hMG average starting dose 228.8±68.7 IU; total average 2356.4±955.1 IU; rFSH average starting dose 152.7±41.1 IU, total average 1639.2±476.9 IU | Not specified per cycle | human | Research PMID 21776876 |
| Intramuscular injection | 600 IU or 900 IU hMG (dosage groups I-V described; 600 IU and 900 IU groups referenced for key findings) | 3 days (600 IU group); 2-day treatment also possible per authors | animal | Research PMID 8720060 |
| subcutaneous injection | 75 IU | 3x per week · 4-6 weeks | men on TRT or post-cycle seeking fertility preservation / spermatogenesis support | [Community] |
| subcutaneous injection | 150 IU | 3x per week · 4-8 weeks | men with hypogonadotropic hypogonadism or severe oligospermia pursuing fertility | [Community] |
| subcutaneous injection | 75 IU | every other day · 6-12 weeks | men coming off anabolic steroid cycles (PCT) with fertility goals | [Community] |
| subcutaneous injection | 150 IU | every other day · 8-16 weeks | men post-cycle with severe spermatogenic suppression or azoospermia | [Community] |
| subcutaneous injection | 75 IU | 2x per week · ongoing (months to years) | men on long-term TRT who want to maintain fertility potential | [Community] |
| intramuscular injection | 150 IU | 3x per week · 4-6 weeks | women undergoing ovarian stimulation in assisted reproduction (ART) context; discussed in biohacker/fertility communities | [Community] |
All studies (14)
- PMID 18583332 Human RCT
Controlled ovarian stimulation (COS) for IVF/ICSI - PMID 19192340 Human RCT
Controlled ovarian stimulation (COS) for IVF/ICSI - PMID 21776876 Human RCT
Controlled ovarian stimulation (COS) for IVF/ICSI - PMID 23080548 Human RCT
Ovulation induction in clomiphene-resistant women - PMID 37480456 Human RCT
Controlled ovarian stimulation (COS) for IVF/ICSI - PMID 12081234 Human observational
Ovulation induction in severe hypogonadotropic amenorrhea - PMID 29676585 Human observational
Endometrial preparation for frozen-thawed embryo transfer (FET) - PMID 31814708 Human observational
Endometrial preparation for frozen-thawed embryo transfer (FET) - PMID 17169561 Mixed
HMG proteins (High Mobility Group) — roles in chromatin, transcription, and disease - PMID 17599239 Mixed
HMG proteins (High Mobility Group) — roles in chromatin, transcription, and disease - PMID 20123065 Mixed
HMG proteins (High Mobility Group) — roles in chromatin, transcription, and disease - PMID 8720060 Animal studies only
Superovulation in cattle (veterinary use) - PMID 19298714
- PMID 20500109
Frequently asked
What is HMG and what is it used for?
The abbreviation 'HMG' refers to several distinct entities in the scientific literature. In the context of fertility treatment, hMG (human menopausal gonadotropin) is a preparation containing FSH and LH activity used to stimulate follicle development for IVF/ICSI, frozen-thawed embryo transfer (PMID 31814708, PMID 29676585), and ovulation induction. 'HMG' also refers to High Mobility Group proteins (chromatin-associated nuclear proteins, PMID 17169561) and HMG-CoA reductase inhibitors (statins used for cholesterol lowering). Please clarify which entity you are asking about.
Is HP-hMG better than rFSH for IVF?
Studies have shown mixed results. An RCT of 280 patients found no significant difference in ongoing pregnancy rate between HP-hMG and rFSH in GnRH antagonist cycles (35.0% vs 32.1%, P=0.61), though rFSH produced more oocytes. A retrospective study (760 patients) similarly found no significant difference in clinical pregnancy rate (49.5% vs 48.9%) or delivery rate. Economic analyses suggest HP-hMG may achieve similar live birth rates at lower cost per live birth (HP-hMG €9,996 vs rFSH €13,009, PMID 19192340; US$3,024 cost saving per live birth in high-responders, PMID 37480456). The best option depends on individual clinical context — please consult a reproductive endocrinologist.
What dose of hMG is used for FET endometrial preparation?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: One large retrospective cohort study used 150 IU hMG every two days from cycle day 10-12 to stimulate follicle development in FET cycles. A separate retrospective analysis used a 'modified hMG stimulated' protocol but did not specify the exact dose in the abstract. Please consult a licensed reproductive specialist for protocol guidance.
What is the risk of OHSS with hMG?
Ovarian hyperstimulation syndrome (OHSS) is a recognized risk with hMG-based stimulation. In a study of women with severe hypogonadotropic amenorrhea, the conventional hMG-hCG method was associated with a 25.7% OHSS rate, the step-down method with 20.0%, and the modified hMG-GnRH method with 0%. A cost-comparison analysis in high-responders noted a reduced OHSS rate as a key advantage of HP-hMG vs rFSH protocols. OHSS risk depends on protocol, population, and individual response — monitoring by a licensed provider is essential.
What dose of hMG should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: Published studies have used doses ranging from 75 IU for 4 days (in a sequential CC/hMG protocol; NOTE: the source study, PMID 23080548, has been retracted) to 150 IU every two days to 600–900 IU over 2–3 days in veterinary superovulation. Human clinical dosing varies considerably by indication, protocol, and individual response. Please consult a licensed healthcare provider.
Can I combine hMG with letrozole?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: A large retrospective cohort (5,901 FET cycles) compared hMG alone, letrozole alone, and letrozole+hMG for endometrial preparation. The letrozole-alone group showed higher clinical pregnancy rates (52.07%) and lower miscarriage (10.53%) and ectopic pregnancy rates (0.97%) compared to hMG alone (47.02%, 14.78%, 1.83% respectively). The letrozole+hMG combination had similar pregnancy rates to letrozole alone. Combination use requires medical supervision.
What are the side effects of hMG?
Based on published studies: OHSS was reported at rates up to 25.7% with conventional hMG-hCG protocols in hypogonadotropic amenorrhea. Higher miscarriage (14.78%) and ectopic pregnancy (1.83%) rates were observed with hMG-alone FET protocols compared to letrozole. Multiple pregnancies are a risk due to multi-follicular development. Note: the abstracts reviewed do not describe the full safety profile. Please consult a licensed reproductive specialist for complete risk information.
What are HMG proteins and what do they do?
HMG (High Mobility Group) proteins are a superfamily of abundant, ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber. They are considered architectural elements of chromatin that dynamically modulate DNA-dependent processes including transcription and replication. The HMG superfamily is divided into subfamilies including HMGA, HMGB, and HMGN proteins, as well as HMG-box transcription factors. Their expression is developmentally regulated; altered levels can lead to developmental abnormalities and disease.
Where can I buy hMG?
I don't recommend vendors or sources. Please consult a licensed provider.